including the impact of the price on access to the drug and the relationship of the price of the drug to its therapeutic health benefits. (C) The risk adjusted value of Federal Government subsidies and investments related to the drug. (D) The costs associated with development of the drug. (E) Whether the drug provided a significant improvement in health outcomes, compared to other therapies available at the time of its approval. (F) The cumulative global revenues generated by the drug. (G) Whether the domestic average manufacturer price of the drug increased during any annual quarter by a percentage that is more than the percentage increase in the consumer price index for all urban consumers for the respective annual quarter. (H) Other factors the Secretary determines appropriate. (c) Petition for determination (1) In general Any person may petition the Secretary, in accordance with section 553(e) of title 5, United States Code, to make an excessive drug price determination for an applicable drug under subsection (b)(2). Not later than 90 days after the date of receipt of such a petition, subject to paragraph (2), the Secretary shall— (A) make a determination under subsection (b)(2) regarding such drug